DUBLIN - STERIS plc (NYSE: STE), a global leader in infection prevention, announced today a quarterly interim dividend of $0.52 per share. The dividend is scheduled to be paid on June 26, 2024, to shareholders of record as of June 12, 2024.
This announcement marks the company's commitment to providing returns to its shareholders. STERIS is recognized for its comprehensive range of products and services aimed at supporting patient care, primarily focusing on infection prevention across healthcare, life sciences, and dental sectors worldwide.
The company's forward-looking statements within the press release caution investors about the various factors that could impact STERIS's performance, including market conditions, regulatory changes, and the effects of public health crises such as the COVID-19 pandemic. These statements are made in accordance with the Private Securities Litigation Reform Act of 1995, which provides certain protections for such forward-looking information.
The press release also mentions the potential effects of the company's previously announced sale of its Dental business segment, including the receipt of necessary regulatory approvals and the realization of expected benefits from the transaction.
Investors are advised to consider these factors, among others detailed in the company’s Annual Report and other securities filings, when evaluating the company's prospects.
STERIS has provided additional information on the U.S. tax treatment of dividends on its investor relations website. The company, however, does not undertake to update any forward-looking statements and advises that actual results could differ materially from those projected.
This dividend distribution news is based on a press release statement from STERIS plc.
InvestingPro Insights
STERIS plc (NYSE: STE) continues to demonstrate its commitment to shareholder returns with its recent dividend announcement. The company's dedication to consistent dividends is underscored by its track record of raising its dividend for 13 consecutive years, a testament to its financial stability and investor-friendly approach.
Reflecting on the company's financial health, an InvestingPro Tip highlights that STERIS has maintained dividend payments for 20 consecutive years, illustrating a long-term strategy of rewarding shareholders.
Investors may find the company's valuation metrics of interest, as STERIS is currently trading at a high earnings multiple, with a P/E Ratio of 36. This suggests that the market has high expectations for the company's future earnings growth.
According to InvestingPro Data, the company boasts a Market Cap of 20.25 billion USD and a Price/Book ratio of 3.16 as of the last twelve months ending Q3 2024. These figures indicate a solid market position and a potentially attractive investment for those looking at asset valuation.
Moreover, STERIS's revenue has shown promising growth, with a 13.04% increase over the last twelve months as of Q3 2024. This growth trajectory is further supported by an InvestingPro Tip that forecasts net income is expected to grow this year. Such financial dynamics could be pivotal for investors assessing the company's future performance, especially in light of the upcoming earnings date on May 8, 2024.
For investors seeking deeper analysis and more comprehensive insights, there are additional InvestingPro Tips available on STERIS. These tips provide a richer understanding of the company's financial landscape and investment potential. To explore these insights and make informed investment decisions, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.